Ghana is first country to approve Oxford malaria vaccine

Breakthrough hailed as highly effective R21 vaccine is cleared by west African country but questions remain over funding

Ghana has become the first country to approve a highly effective malaria vaccine developed at Oxford university in the UK.

The R21/Matrix-M vaccine, the first to exceed the World Health Organization's target of 75% efficacy, has been cleared for use by Ghana's Food and Drugs Authority in children aged 5-36 months, the group at highest risk of death from malaria.